deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT03373786

A Study of RG-012 in Subjects With Alport Syndrome

A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome

Sponsor: Genzyme, a Sanofi Company

Conditions Alport Syndrome
Interventions RG012
Updated 14 times since 2017 Last updated: Apr 21, 2022 Started: Dec 22, 2017 Primary completion: May 20, 2019 Completion: May 20, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Alport Syndrome, this trial is completed. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 14 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — May 2022 [monthly]

    Completed PHASE1

  5. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 9 earlier versions

  1. Feb 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

  3. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  4. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  6. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  7. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE1

  8. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE1

  9. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genzyme, a Sanofi Company
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations